Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division on the S. Luigi Hospital, Orbassano (Torino), and head of the Division of Oncology at College of Torino, Italy, discusses immunotherapy within the context of precision medication in lung most cancers.Within the oncology area, there’s a motion towards precision medication as a method to tailor therapy to a affected person’s specific illness traits. Immunotherapy is an rising pillar within the systemic therapy of non–small cell lung most cancers usually, says Scagliotti, and is appropriately thought of to be within the realm of precision medication. It’s because immunotherapy isn’t a one-size-fits-all strategy, and precision medication relies on tailoring remedy to the actual affected person.At the moment, PD-L1 expression is without doubt one of the biomarkers that’s typically used to point affected person will reply, as it’s simply assessed in medical apply, explains Scagliotti. Based mostly on present knowledge, it may be thought of as an enrichment issue, he provides. General response charges and durations of response noticed in medical trials have been proven to be extra favorable in sufferers who’re PD-L1–optimistic.